English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61833
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Neuregulins and Cancer

AuthorsMontero, Juan Carlos ; Rodríguez-Barrueco, Ruth; Ocaña, Alberto; Díaz-Rodríguez, Elena ; Esparís-Ogando, Azucena ; Pandiella, Atanasio
Issue Date2008
PublisherAmerican Association for Cancer Research
CitationClinical Cancer Research 14: 3237-3241 (2008)
AbstractThe neuregulins represent the largest subclass of polypeptide factors of the epidermal growth factor family of ligands. These molecules are synthesized as membrane-bound, biologically active growth factors that act by binding to the HER/ErbB receptor tyrosine kinases. Preclinical data have indicated that increased expression and function of neuregulins may provoke cancer. Furthermore, neuregulin expression has been detected in several neoplasias, and their presence may correlate with response to treatments that target the HER receptors such as trastuzumab. In addition, the neuregulins have also been implicated in resistance to anti-HER therapies. Therefore, targeting of the neuregulins may be helpful in neoplastic diseases in which these polypeptide factors contribute to tumor generation and/or maintenance. © 2008 American Association for Cancer Research.
Identifiersdoi: 10.1158/1078-0432.CCR-07-5133
issn: 1078-0432
e-issn: 1557-3265
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.